ZA918592B - An animoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside - Google Patents

An animoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside

Info

Publication number
ZA918592B
ZA918592B ZA918592A ZA918592A ZA918592B ZA 918592 B ZA918592 B ZA 918592B ZA 918592 A ZA918592 A ZA 918592A ZA 918592 A ZA918592 A ZA 918592A ZA 918592 B ZA918592 B ZA 918592B
Authority
ZA
South Africa
Prior art keywords
group
carbon atoms
chain
chem
stands
Prior art date
Application number
ZA918592A
Other languages
English (en)
Inventor
William J Novick Jr
J Novick William Jr
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of ZA918592B publication Critical patent/ZA918592B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
ZA918592A 1990-10-30 1991-10-29 An animoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside ZA918592B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/606,018 US5039666A (en) 1990-10-30 1990-10-30 Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside

Publications (1)

Publication Number Publication Date
ZA918592B true ZA918592B (en) 1992-07-29

Family

ID=24426160

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA918592A ZA918592B (en) 1990-10-30 1991-10-29 An animoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside

Country Status (16)

Country Link
US (1) US5039666A (xx)
EP (1) EP0483634B1 (xx)
JP (1) JP3003333B2 (xx)
KR (1) KR0139199B1 (xx)
AT (1) ATE133072T1 (xx)
AU (1) AU640056B2 (xx)
CA (1) CA2054471C (xx)
DE (1) DE69116503T2 (xx)
DK (1) DK0483634T3 (xx)
ES (1) ES2083500T3 (xx)
GR (1) GR3018824T3 (xx)
HU (1) HU213509B (xx)
IE (1) IE70670B1 (xx)
IL (1) IL99874A (xx)
PT (1) PT99358B (xx)
ZA (1) ZA918592B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2191013T3 (es) * 1992-03-04 2003-09-01 Cell Therapeutics Inc Compuestos de xantina enantiomeros hidroxilados.
JP3076672B2 (ja) * 1992-06-18 2000-08-14 三井化学株式会社 キノリン誘導体のフマル酸塩
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994016704A1 (en) * 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
JPH09511496A (ja) * 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド 細胞内メッセンジャー
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
DE19823396A1 (de) * 1998-05-26 1999-12-02 Bayer Ag Synergistische insektizide Mischungen
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
AU2004224788A1 (en) * 2003-03-26 2004-10-07 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
WO2006037335A2 (en) * 2004-10-06 2006-04-13 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
US7439343B2 (en) * 2005-09-01 2008-10-21 Rensselaer Polytechnic Institute Aminoglycoside-polyamine displacers and methods of use in displacement chromatography
WO2009152202A2 (en) * 2008-06-11 2009-12-17 Utah State University New aminoglycosides: synthesis and use as antifungals
US9669044B2 (en) 2010-12-14 2017-06-06 Utah State University Aminoglycoside and azole compositions and methods
US8865665B2 (en) 2010-12-14 2014-10-21 Utah State University Aminoglycosides: synthesis and use as antifungals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029882A (en) * 1974-03-19 1977-06-14 Schering Corporation Selective acylation of the C-1 amino group of aminoglycoside antibiotics
US4002742A (en) * 1974-03-19 1977-01-11 Schering Corporation 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor
US4235892A (en) * 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
EP0414175A3 (en) * 1989-08-22 1992-04-01 Hoechst Aktiengesellschaft Use of xanthine derivatives to reduce nephrotoxicity

Also Published As

Publication number Publication date
JP3003333B2 (ja) 2000-01-24
IL99874A0 (en) 1992-08-18
ATE133072T1 (de) 1996-02-15
IE70670B1 (en) 1996-12-11
GR3018824T3 (en) 1996-04-30
HU913392D0 (en) 1992-01-28
DE69116503T2 (de) 1996-06-20
DE69116503D1 (de) 1996-02-29
US5039666A (en) 1991-08-13
EP0483634A3 (en) 1992-10-14
JPH04282315A (ja) 1992-10-07
PT99358B (pt) 1999-03-31
CA2054471C (en) 1998-09-22
DK0483634T3 (da) 1996-05-20
KR0139199B1 (ko) 1998-05-15
AU8680291A (en) 1992-05-07
IL99874A (en) 1995-08-31
HU213509B (en) 1997-07-28
EP0483634A2 (en) 1992-05-06
KR920007630A (ko) 1992-05-27
PT99358A (pt) 1992-09-30
AU640056B2 (en) 1993-08-12
IE913775A1 (en) 1992-05-22
CA2054471A1 (en) 1992-05-01
ES2083500T3 (es) 1996-04-16
HUT60136A (en) 1992-08-28
EP0483634B1 (en) 1996-01-17

Similar Documents

Publication Publication Date Title
EP0483634A3 (en) An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside
UA37230C2 (uk) Полі-1-н-алкенаміни та склади палива або мастильного засобу, що їх містять
GR3015194T3 (en) Indolocarbazole derivatives, process for their preparation and medicines containing same.
KR920701200A (ko) 신규의 4h-3,1-벤조옥사진-4-온 유도체
MY108076A (en) Cationic compound and cleaning composition.
AU660469B2 (en) Pharmacologically active hydrazine derivatives and processes for the preparation thereof
ES8200679A1 (es) Un procedimiento para la preparacion de derivados de carboestirilo.
KR920009399A (ko) 면역 억제 활성을 갖는 약제를 제조하기 위한 크산틴의 용도
BR9604907B1 (pt) derivados de nucleosidios homocarbociclico de pirimidinodiona substituìda antiviral e composição contendo derivados de nucleosidios homocarbociclico de pirimidinodiona substituìda antiviral com princìpios ativos.
HU901484D0 (en) Hydroxi-alkane-carboxylic acid derivatives, processes for producing and utilizing them
KR920009397A (ko) 사람 레트로바이러스의 복제를 억제하는데 효과적인 약제를 제조하기 위한 크산틴의 용도
MXPA94001822A (es) Derivados de acido aciloxihexanoico.
ES8104182A1 (es) Procedimiento para preparar diaminas alquiladas
DE3275083D1 (en) Cycloaliphatic alcohols
BG60269B2 (en) Process for the preparation of pyrimidine trione derivatives